-transparent.png){kind=logo}
Lipoxin A (LXA) was prepared by incubation of either (15S)-15-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid (15-HETE) or (15S)-15-hydroperoxy-5,8,11-cis-13-trans-eicosatetraenoic (15-HPETE) with human leukocytes stimulated by either the ionophore A23187 or the chemotactic peptide fMet-Leu-Phe. Comparison with four trihydroxyeicosatetraenoic acids prepared by total synthesis showed that biologically derived LXA is 5S,6R,15S)-5,6,15-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid. Three isomers of LXA were also identified in extracts of leukocytes utilizing an improved isolation procedure. These were (5S,6S,15S)-5,6,15-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid (6S-LXA), (5S,6R,15S)-5,6,15-trihydroxy-7,9,11,13-trans-eicosatetraenoic acid (11-trans-LXA), and (5S,6S,15S)-5,6,15-trihydroxy-7,9,11,13-trans-eicosatetraenoic acid (6S-11-trans-LXA). 18O2-labeling studies indicated that formation of LXA and its isomers occurred with incorporation of 18O at their C-5 but not C-6 positions. These results suggest that 15-hydroxy-5,6-epoxy-7,9,13-trans-11-cis-eicosatetraenoic acid or its equivalent may serve as one intermediate in the biosynthesis of LXA and 6S-LXA. When added to guinea pig lung strips LXA provoked contractions which were slow in onset and long lasting. In addition, dose response studies showed that biologically derived LXA and synthetic LXA were indistinguishable in this bioassay whereas synthetic 6S-LXA and biologically derived 6S-LXA did not share this activity. Taken together, these results suggest that activated leukocytes utilize exogenous 15-HETE to generate lipoxins which in turn can modulate cellular responses.
C N Serhan, and
K C Nicolaou, and
S E Webber, and
C A Veale, and
S E Dahlén, and
T J Puustinen, and
B Samuelsson
April 1986,
Proceedings of the National Academy of Sciences of the United States of America,
C N Serhan, and
K C Nicolaou, and
S E Webber, and
C A Veale, and
S E Dahlén, and
T J Puustinen, and
B Samuelsson
January 1985,
Advances in prostaglandin, thromboxane, and leukotriene research,
C N Serhan, and
K C Nicolaou, and
S E Webber, and
C A Veale, and
S E Dahlén, and
T J Puustinen, and
B Samuelsson
May 1969,
Journal of the American Chemical Society,
C N Serhan, and
K C Nicolaou, and
S E Webber, and
C A Veale, and
S E Dahlén, and
T J Puustinen, and
B Samuelsson
March 2006,
Prostaglandins & other lipid mediators,
C N Serhan, and
K C Nicolaou, and
S E Webber, and
C A Veale, and
S E Dahlén, and
T J Puustinen, and
B Samuelsson
October 2005,
American journal of respiratory and critical care medicine,
C N Serhan, and
K C Nicolaou, and
S E Webber, and
C A Veale, and
S E Dahlén, and
T J Puustinen, and
B Samuelsson
January 1986,
Advances in prostaglandin, thromboxane, and leukotriene research,
C N Serhan, and
K C Nicolaou, and
S E Webber, and
C A Veale, and
S E Dahlén, and
T J Puustinen, and
B Samuelsson
October 1969,
Journal of the American Chemical Society,
C N Serhan, and
K C Nicolaou, and
S E Webber, and
C A Veale, and
S E Dahlén, and
T J Puustinen, and
B Samuelsson
April 1970,
The Biochemical journal,
C N Serhan, and
K C Nicolaou, and
S E Webber, and
C A Veale, and
S E Dahlén, and
T J Puustinen, and
B Samuelsson
October 1967,
The Biochemical journal,
C N Serhan, and
K C Nicolaou, and
S E Webber, and
C A Veale, and
S E Dahlén, and
T J Puustinen, and
B Samuelsson
September 1993,
Archives of biochemistry and biophysics,
